Overview

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Status:
Terminated

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's lymphoma (NHL). Both agents are effective in treating relapsed and refractory NHL. Administer of the agents together may sensitize the cells to the radiation from Tositumomab I-131.

Phase:

Phase 2

Details

Lead Sponsor:

Rush University Medical Center

Collaborators:

GlaxoSmithKline
Millennium Pharmaceuticals, Inc.

Treatments:

Antibodies, Monoclonal
Bortezomib
Iodine-131 anti-B1 antibody
Tositumomab I-131